PDCD1 and hepatocellular carcinoma: To our knowledge, this is the first and longest follow-up prospective clinical trial to evaluate the efficacy and safety of the triple combination of lenvatinib, TACE and PD-1 inhibitors as conversion therapy for unresectable HCC.